TSX up after index logs fresh record high close
Investing.com - Truist Securities raised its price target on Treace Medical Concepts Inc (NASDAQ:TMCI) to $8.00 from $6.60 while maintaining a Hold rating on the stock. According to InvestingPro data, the medical device company, currently valued at $457 million, shows a GOOD overall Financial Health Score despite not being profitable in the last twelve months.
The price target increase follows Treace Medical’s New York City Investor Day, which showcased three new product launches designed to expand the company’s portfolio to address all classes of minimally invasive (MIS) bunion surgery. The company maintains an impressive 80% gross margin and has achieved 7.7% revenue growth over the last twelve months.
The new offerings include two MIS Osteotomy solutions and Speedplate MTP for big toe arthritis, which should strengthen Treace Medical’s position in the growing MIS osteotomy market that represents approximately 70% of the opportunity where the company has previously had gaps.
Truist Securities expects these new products to drive accelerating double-digit growth in the second half of 2025 and beyond, but maintains its Hold rating pending greater confidence that the new rollouts can sustain accelerated growth trends beyond easy comparisons in an increasingly competitive market.
The higher price target reflects some group multiple expansion since Truist’s last valuation update and increasing visibility to a growth acceleration trajectory in the second half of 2025 through 2026, with the new target based on 2x 2026 estimated EV/Sales versus approximately 1.5x previously.
In other recent news, Treace Medical Concepts Inc. reported its second-quarter 2025 earnings, revealing a slightly better-than-expected performance. The company posted a loss of $0.28 per share, which was an improvement over the anticipated loss of $0.29 per share. Additionally, Treace Medical’s revenue surpassed forecasts, reaching $47.39 million compared to the expected $47.08 million. These results indicate a positive deviation from analyst projections. There were no major mergers or acquisitions reported in the recent updates. Analyst upgrades or downgrades have not been highlighted in the latest reports. Investors might find these developments noteworthy as they reflect the company’s current financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.